文献速递肾移植肾小球疾病

环孢素降低霉酚酸暴露40%而其他钙调神经磷酸酶抑制剂无此效应

How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
PubMed 文献 · Kidney Int · 2021-07-17

肾移植和肾小球疾病常联用钙调神经磷酸酶抑制剂(CNI)与霉酚酸酯。环孢素通过抑制霉酚酸的肠肝循环,使霉酚酸AUC较他克莫司或沃罗孢素联用(或无CNI联用)时显著降低40%。霉酚酸酯的最佳剂量可能取决于联用的CNI,停用环孢素后需警惕霉酚酸相关不良反应的出现。

要点

  • 环孢素抑制霉酚酸肠肝循环,使AUC降低40%。
  • 霉酚酸酯最佳剂量需考虑联用的CNI类型。
  • 停用环孢素后可能需监测霉酚酸相关不良反应。

核心结论

  • 环孢素联用使霉酚酸AUC较他克莫司、沃罗孢素或无CNI联用时显著降低40%。

研究设计与样本

  • 本文为mini综述,总结环孢素与霉酚酸之间药物相互作用的机制与临床意义。

主要发现

  • 环孢素通过抑制霉酚酸的肠肝循环,使霉酚酸AUC较他克莫司或沃罗孢素联用(或无CNI联用)时降低40%。
  • 霉酚酸酯的最佳剂量可能取决于联用的CNI类型。
  • 停用环孢素联用后可能出现霉酚酸相关不良反应。

临床怎么用

  • 联用环孢素时需注意霉酚酸暴露降低,调整霉酚酸酯剂量应结合所用CNI。
  • 停用环孢素后应监测霉酚酸相关不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The most frequently used immunosuppressive treatment in kidney transplant recipients is the combination therapy of a calcineurin inhibitor (CNI) and mycophenolate mofetil, with or without corticosteroids. Cyclosporine and tacrolimus are the 2 CNIs registered for this indication. Also, in the treatment of glomerular diseases, CNIs and mycophenolate are being used on a worldwide scale, either alone or as combined treatment. In January 2021, the US Food and Drug Administration approved voclosporin, a novel CNI, for the treatment of adult patients with active lupus nephritis. There is a clinically relevant drug-drug interaction between cyclosporine and mycophenolate. As a result of cyclosporine-induced inhibition of the enterohepatic recirculation of mycophenolate, the mycophenolic acid area under the curve is significantly lower (40%) in case of cyclosporine coadministration compared with cotreatment with either tacrolimus or voclosporin (or no CNI cotreatment). The aim of this mini review is to summarize this potential drug-drug interaction and explain how cyclosporine affects the pharmacokinetics of mycophenolate. The optimal dose of mycophenolate mofetil is likely to depend on the CNI with which it is coadministered. Furthermore, clinical implications are discussed, including the potential emergence of mycophenolic acid-related adverse effects after discontinuation of cyclosporine cotreatment.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. van Gelder T. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney Int. 2021. PMID: 34284043. doi:10.1016/j.kint.2021.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。